Barrett's Esophagus Clinical Trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 1376 clinical trials
Tissue Retractors for Radiation Therapy of Head and Neck Tumors
The most effective approach to reducing acute toxicity is to cut out healthy tissue from the radiation field. The distance between the tumor and normal tissue can be individually increased using personalized, 3D printer-based tissue retractors (GWR). Even the smallest geometric changes lead to a significant dose reduction in normal …
- 0 views
- 19 Feb, 2024
- 1 location
Vaccine Responsiveness After CAR-T Cell Therapy
This phase I trial will use the inactivated rabies virus vaccine to assess immune function in patients who previously underwent B cell targeted chimeric antigen receptor-modified T cell immunotherapy (CARTx). A cohort of healthy volunteers will also be enrolled as a comparator group. CARTx is a new treatment for patients …
- 0 views
- 19 Feb, 2024
- 1 location
Nabilone for Non-motor Symptoms in Parkinson's Disease
Nabilone acts as a partial agonist on both Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) receptor in humans and therefore mimics the effect of THC but with more predictable side effects and less euphoria. Eligible patients will be re-tapered in an open-label nabilone dose optimization phase followed by an open-label …
- 150 views
- 19 Feb, 2024
- 1 location
Coping With 2020 - No Health Without Mental Health
In this research project we want to examine the use and the effects of a digital self-guided psychological intervention with the aim to increase coping and to reduce psychological problems during and after the pandemic. The participants will be randomized to either an intensive group (new module every 3rd day) …
- 0 views
- 19 Feb, 2024
- 1 location
Randomized Trial of Transcatheter Valve-in-Valve vs Redo Surgery for Bioprosthetic Mitral Dysfunction
In particular, late prosthesis durability and hemodynamic performance after TsMViV are largely unknown and need to be elucidated before widely indicated, especially among younger and low-risk surgical candidates with failed mitral bioprostheses.
- 0 views
- 19 Feb, 2024
- 1 location
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Nilotinib is a capsule taken by mouth twice a day. Paclitaxel will be given intravenously by peripheral line or central line once a week for the first 3 weeks of each cycle. Participants will keep a medicine diary.
- 0 views
- 19 Feb, 2024
- 1 location
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and SL-401 with chemotherapy may be an effective treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
- 0 views
- 19 Feb, 2024
- 1 location
Effect of the Postbiotics on Complications Treatment in Elderly Hemodialysis Patients
The purpose of the trial is to explore the effect of exogenous postbiotics supply on the quality of life and nutritional status of elderly hemodialysis patients.Participants will be devided into intervention group and placebo group in an 1:1 ratio.They will:In the treatment period for 12 weeks, intervention group receives postbiotics …
- 0 views
- 16 May, 2025
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)
Funding to progress to Phase 2 of this trial has been obtained. It is anticipated 120 subjects participating in Phase 1 will be screened for eligibility for Phase 2 (separate consent and eligibility from Phase 1).
- 0 views
- 19 Feb, 2024
- 1 location
NUVOLA TRIAL Open-label Multicentre Study
In a recent phase Ib/II study, olaparib plus weekly carboplatin and paclitaxel in relapsed ovarian cancer patients was shown to be safe, well tolerated and effective, especially in germline BRCA mutated (gBRCAmut) patients. Possibly, the addition of a PARP inhibitor (olaparib) to NACT in HGSOC patient with germline or somatic …
- 0 views
- 19 Feb, 2024
- 1 location